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Introduction
Osteoporosis is a complex disease characterized by a
decrease in bone mass and alterations of bone quality
leading to increased bone fragility and fracture risk. The
increasing worldwide incidence of osteoporosis requires
the use of effective treatments. The aim of antiosteoporotic
treatments is to improve bone strength and thus to decrease
the risk of fracture [1, 2]. Bone quality includes several
aspects of bone composition and structure, including
microstructure, bone turnover, the degree of mineralization,
and the extent of microdamage. Bone quality is being given
increased importance as recent observations demonstrate
that traditional measures of bone density do not always
predict fracture risk reliably [3].
At present, the major noninvasive measurement avail-
able for the diagnosis of osteoporosis is the measurement of
areal bone mineral density (BMD) by dual-energy X-ray
absorptiometry (DXA). Fracture risk prediction in the
individual patient also relies mainly on BMD measure-
ments. The diagnosis of osteoporosis measured by DXA, is
a BMD of ≥2.5 standard deviations below the mean for
young adults. However, many lines of evidence indicate that
the decreased bone strength characteristic of osteoporosis is
only partially accounted for by BMD and the remainder is
dependent on material and structural properties of bone
tissue, the bone microstructure [4–10]. Furthermore, the
alterations in bone microstructure are not captured by BMD
measurements. Measurements of BMD are useful in post-
menopausal osteoporosis and other conditions of significant
demineralization.
Knowledge of bone microstructure is a clue for under-
standing osteoporosis pathophysiology and improving its
diagnosis and treatment; the response of microstructure
parameters to treatment should allow assessment of the real
efficacy of the osteoporosis therapy.
Assessment of bone microstructure
The gold standard for investigation of bone disease remains
the histomorphometry or quantitative histology of iliac
crest biopsies, which has greatly enhanced our understand-
ing of normal bone microstructure, remodeling, and
strength, as well as the effects on bone of various diseases
and treatments for osteoporosis [11]. However, this tech-
nique is invasive, and thus longitudinal measurements of
bone structure at the same location are difficult to follow
up. In addition, bone biopsies are performed in regions of
low load and low fracture prevalence [12].
Recently, there has been great interest in noninvasive
imaging techniques that enable assessment of bone micro-
structure in vivo at weight-bearing and non-weight-bearing
skeletal sites that may be affected by osteoporosis. As new
products and methods have been developed, focusing more
on bone fragility, it has been essential to develop effective
and sensitive means to assess fracture repair [13]. New
techniques are now available which are able to provide
structural information about local and systemic skeletal
health and the pathophysiology of bone fragility [13].
These include high-resolution magnetic resonance imaging
(HR-MRI), micro-CT (µCT), and synchrotron radiation
µCT [4, 14]. It has been demonstrated that microstructure
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parameters should be obtained by using several of the
above-mentioned techniques. Micro-CT, micro-MRI, and
synchrotron also allow the measurement in 3D of the
trabecular microstructure in a nondestructive way on bone
specimens [3]. In addition, the application of μCT to bone
biopsy specimens has improved assessment of trabecular
microstructure because the analysis is truly volumetric and
encompasses the entire biopsy sample rather than being
limited to several histological sections.
One recently developed noninvasive technique, HR-
pQCT (Xtreme CT, Scanco Medical AG, Brüttisellen,
Switzerland), can perform human in vivo measurements at
peripheral sites including the radius and a weight-bearing
site, i.e., the tibia. This technique yields 3D images of
sufficiently high resolution (∼82 μm). The standard HR-
pQCT morphological measurement protocol includes a
direct measurement of trabecular number (Tb.N), and
derived measurements of bone volume ratio (BV/TVd),
trabecular thickness (Tb.Th), trabecular separation (Tb.Sp),
and cortical thickness (Ct.Th) [15, 16].
Treatment effects: from BMD…
Both anti-resorptive and anabolic interventions affect
BMD. The majority of clinical studies on anti-resorptive
agents, such as bisphosphonates, denosumab, selective
estrogen receptor modulators, and estrogen have shown
an increase in BMD that parallels the decreased risk of
fracture [17–19]. Raloxifene and alendronate treatments
have also been associated with a reduction in vertebral
fracture, but the effect on BMD at the femoral neck and
spine is less pronounced with treatment with raloxifene
(+3%) than alendronate at the spine and trochanter
(+8%) [17, 20–22]. However, it has been observed that
improvement in spine BMD during treatment with anti-
resorptive drugs accounted for a predictable but small part
of the observed reduction in the risk of vertebral fracture
[23].
In preclinical studies comparing determinants of bone
strength, such as BMD, bone external dimensions, and
trabecular bone morphology, BMD was systematically inves-
tigated and, independently of the laboratories performing the
study or of the mammalian species investigated (pig, monkey,
rat, mouse), predicted 50–75% of the variation in ultimate
strength [1, 24, 25]. BMD measurements are therefore still
useful for predicting bone strength.
Strontium ranelate has been shown to significantly
increase bone mineral density at the lumbar spine, femoral
neck, and total hip, which is significantly related to fracture
risk reduction [26–28]. A post-hoc analysis of pooled data
from the SOTI and TROPOS studies demonstrated that
changes of BMD at the femoral neck after 3 years of
treatment were predictive of vertebral fracture risk reduc-
tion, with each 1% increase in femoral neck BMD found to
be associated with a 3% reduction in vertebral fracture risk.
Changes in BMD thus explained 76% of the fracture risk
reduction observed after 3 years of treatment [29]. An
increase in femoral neck BMD after 1 year of treatment was
also associated with a reduction in new vertebral fractures
after 3 years of treatment (p=0.04). During 3 years of
treatment, femoral neck BMD changes were also associated
with hip fracture risk reduction [29] suggesting that femoral
neck BMD assessment may be a more appropriate monitoring
tool than lumbar spine BMD measurements in strontium
ranelate-treated patients.
...to microstructure
A specific analysis of microstructure was performed on 41
bone biopsies obtained from patients participating in the
SOTI and TROPOS studies and the biopsies were exam-
ined using three-dimensional µCT [11]. Compared with
placebo (n=21), biopsies obtained from strontium ranelate-
treated patients (n=20) demonstrated a significant increase
in the number of trabeculae (+14%; p=0.05), decrease in
trabecular separation (−16%; p=0.04) and an increase in
cortical thickness (+18%; p=0.008). There was also a shift
in trabecular structure from rod-like to plate-like configu-
ration resulting in an improved trabecular structural model
index and substantially stronger bone in strontium-treated
compared with untreated patients (−22%; p=0.01) [11].
These changes in trabecular and cortical microstructure are
likely to improve the biomechanical properties of bone and
contribute to the anti-fracture efficacy observed with
strontium ranelate.
In a recent head-to-head longitudinal study, the effects of
strontium ranelate and alendronate on microstructure were
compared. Eighty-eight women aged 50 or over with
postmenopausal osteoporosis were randomized to SR
2 g/day or ALN 70 mg/week for 2 years. Microstructure
of weight-bearing distal tibia bone was assessed by the
aforementioned HR-pQCT after 3, 6, 12, 18, and 24 months
of treatment. Baseline characteristics were similar in both
groups: age, 63.7±7.4 years; lumbar and hip T-score, −2.7±
0.9 g/cm2 and −2.0±0.8 g/cm2, respectively. After 1 year of
treatment, BMD increases were similar to results from
pivotal trials (L1–L4, +5.7% and +5.1%; total hip, +3.3%
and +2.2%, in SR and ALN groups, respectively). For bone
microstructure, mean increases of +5.3% (p<0.001) for
C.Th, +2.0% (p=0.002) for BV/TV and +2.1% (p=0.002)
for trabecular density were found in the SR group, compared
to no change in the ALN group (1.3% p=0.130; 0.6%
p=0.725 and 0.6% p=0.645, for corresponding variables,
respectively), with thus a significant between-group differ-
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ence in favor of SR (p=0.045, p=0.048 and p=0.035, for
C.Th, BV/TV, and trabecular density, respectively). Improve-
ment in microstructure was associated in the SR group with
significant decrease in heterogeneity of trabecular network
(−3.6±8.6%, p=0.007). This study demonstrated that stron-
tium ranelate had significantly higher effects than alendro-
nate on distal tibia microstructure including cortical and
trabecular variables, in women with postmenopausal osteo-
porosis after 1 year of treatment [30]. Whether these changes
translate into a commensurate reduction in fracture rate
should be determined in the future.
Conclusion
BMD remains a good predictor of fracture risk, but many
other factors contribute to bone strength, such as bone
geometry, cortical thickness, and porosity as well as trabecular
bonemorphology. Advances in the assessment of bone quality
in recent years have provided new insights into bone fragility
in both untreated and treated bone disease. As an example,
strontium ranelate treatment was associated with improved
bone microstructure. The development of new technologies,
which now allow in vivo noninvasive evaluation of bone, are
important for the longitudinal monitoring of bone quality
measurements and it can be envisaged that the HR-pQCT
technique will be employed as standard protocol in the future
for improved diagnosis and assessing the treatment effects of
diseases such as osteoporosis.
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